RGNX
REGENXBIO Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -30.0% ·
share flow -13.0% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 93.42K | $730,149 | n/a | n/a |
| Q2 2026 | 76 | 0 | 31.71M | $379.43M | +8 | −8 |
| Q1 2026 | 78 | -5 | 30.64M | $255.01M | +3 | −8 |
| Q4 2025 | 83 | +2 | 30.25M | $435.60M | +2 | n/a |
| Q3 2025 | 14 | -1 | 26.58M | $256.50M | n/a | −1 |
| Q2 2025 | 12 | 0 | 15.85M | $130.14M | n/a | n/a |
| Q1 2025 | 9 | -3 | 5.03M | $35.96M | +1 | −4 |
| Q4 2024 | 12 | +4 | 6.91M | $53.43M | +4 | n/a |
| Q3 2024 | 7 | -3 | 1.79M | $18.80M | n/a | −3 |
| Q2 2024 | 10 | n/a | 2.06M | $24.11M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.09M | +4.2% | $11.42M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 261.16K | -14.8% | $2.74M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 203.23K | +60.8% | $2.13M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Two Sigma Investments ✦ | 125.93K | -29.9% | $1.32M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 55.11K | -61.4% | $578,062 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 36.26K | +77.9% | $380,336 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 21.93K | +3.9% | $231,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $1.73M | was 0.0% |
| Marshall Wace | $457,388 | was 0.0% |
| Wellington Management | $382,028 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 177 holders, 39.19M shares, $343.14M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 53.41K sh @ 9.36 · $499,676
Director · 49.20K sh @ 9.14 · $449,706
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology